Lowest-Rated StocksLowest-RatedNASDAQ:FATE Fate Therapeutics (FATE) Stock Price, News & Analysis → Will this AI Micro-Cap be Bigger than NVIDIA? (From Behind the Markets) (Ad) Free FATE Stock Alerts $3.57 -0.04 (-1.11%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$3.54▼$4.0750-Day Range$3.43▼$6.7652-Week Range$1.63▼$8.83Volume2.88 million shsAverage Volume2.68 million shsMarket Capitalization$406.37 millionP/E RatioN/ADividend YieldN/APrice Target$6.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Fate Therapeutics alerts: Email Address Fate Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.21 Rating ScoreUpside/Downside89.1% Upside$6.75 Price TargetShort InterestBearish19.63% of Shares Sold ShortDividend StrengthN/ASustainability-0.70Upright™ Environmental ScoreNews Sentiment0.77Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.90) to ($1.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.30 out of 5 starsMedical Sector130th out of 913 stocksBiological Products, Except Diagnostic Industry13th out of 152 stocks 4.1 Analyst's Opinion Consensus RatingFate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.21, and is based on 4 buy ratings, 9 hold ratings, and 1 sell rating.Amount of Analyst CoverageFate Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Fate Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted19.63% of the outstanding shares of Fate Therapeutics have been sold short.Short Interest Ratio / Days to CoverFate Therapeutics has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Fate Therapeutics has recently increased by 7.35%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldFate Therapeutics does not currently pay a dividend.Dividend GrowthFate Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreFate Therapeutics has received a 75.52% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Fate Therapeutics is -0.70. Previous Next 2.6 News and Social Media Coverage News SentimentFate Therapeutics has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Fate Therapeutics this week, compared to 3 articles on an average week.Search Interest6 people have searched for FATE on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Fate Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fate Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.00% of the stock of Fate Therapeutics is held by insiders.Percentage Held by Institutions97.54% of the stock of Fate Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fate Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Fate Therapeutics are expected to grow in the coming year, from ($1.90) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fate Therapeutics is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fate Therapeutics is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFate Therapeutics has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Fate Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading Academywhy 99.94% won’t make you moneyI believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's always a catch in life. You NEED to use a specific system when you trade them.Click here to download my options trading cheat sheet (5-7 stocks inside here) About Fate Therapeutics Stock (NASDAQ:FATE)Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Read More FATE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FATE Stock News HeadlinesJune 18 at 1:47 AM | americanbankingnews.comHead-To-Head Contrast: Protara Therapeutics (NASDAQ:TARA) vs. Fate Therapeutics (NASDAQ:FATE)June 13, 2024 | prnewswire.comFATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the FirmJune 11, 2024 | americanbankingnews.comFate Therapeutics, Inc. (NASDAQ:FATE) Given Average Recommendation of "Hold" by AnalystsJune 4, 2024 | globenewswire.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)May 29, 2024 | globenewswire.comFate Therapeutics to Present at 2024 Jefferies Global Healthcare ConferenceMay 28, 2024 | finance.yahoo.comNew Memoir "Echoes of Fate: From Birth to the Last Heartbeats" Captures the Essence of Human Existence and LegacyMay 16, 2024 | markets.businessinsider.comFate Therapeutics: Advancements and Differentiation in Autoimmune and Cancer Therapies Support Buy RatingMay 14, 2024 | markets.businessinsider.comHold Rating on Fate Therapeutics Amid Pending Clinical Data and Strategic Pipeline FocusMay 13, 2024 | seekingalpha.comFate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call TranscriptMay 13, 2024 | finance.yahoo.comFate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call TranscriptMay 11, 2024 | finance.yahoo.comFate Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In LineMay 10, 2024 | markets.businessinsider.comFate Therapeutics: Strategic Shifts Prompt Hold Rating Amidst Awaited Clinical ResultsMay 10, 2024 | finance.yahoo.comFate Therapeutics Inc (FATE) Q1 2024 Earnings: Mixed Financial Performance Amid Clinical ...May 9, 2024 | investorplace.comFATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | msn.comFate Therapeutics GAAP EPS of -$0.47 in-line, revenue of $1.93M beats by $0.67MMay 9, 2024 | sfgate.comFate Therapeutics: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comFate Therapeutics Reports First Quarter 2024 Financial Results and Business UpdatesMay 9, 2024 | globenewswire.comFate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell ProgramMay 8, 2024 | markets.businessinsider.comHere's what to expect from Fate Therapeutics's earningsMay 8, 2024 | msn.comFate Therapeutics Q1 2024 Earnings PreviewMay 6, 2024 | finance.yahoo.comFate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational UpdatesMay 3, 2024 | globenewswire.comFate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual MeetingMay 2, 2024 | finance.yahoo.comAskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting 2024May 2, 2024 | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)April 29, 2024 | seekingalpha.comFate Therapeutics: As Its Rally Fizzles, We May Be Near The BottomSee More Headlines Receive FATE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/17/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FATE CUSIPN/A CIK1434316 Webwww.fatetherapeutics.com Phone(858) 875-1800FaxN/AEmployees181Year FoundedN/APrice Target and Rating Average Stock Price Target$6.75 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+84.4%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($1.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-160,930,000.00 Net Margins-2,933.79% Pretax Margin-2,933.79% Return on Equity-46.49% Return on Assets-34.48% Debt Debt-to-Equity RatioN/A Current Ratio8.69 Quick Ratio8.69 Sales & Book Value Annual Sales$63.53 million Price / Sales6.40 Cash FlowN/A Price / Cash FlowN/A Book Value$3.74 per share Price / Book0.95Miscellaneous Outstanding Shares113,830,000Free Float108,140,000Market Cap$406.37 million OptionableOptionable Beta1.90 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. J. Scott Wolchko (Age 54)Founder, CEO, President & Director Comp: $920.4kMr. Edward J. Dulac III (Age 48)Chief Financial Officer Comp: $612.5kMs. Cindy R. Tahl J.D. (Age 51)General Counsel, Corporate Secretary & Compliance Officer Comp: $612.5kDr. Bahram Valamehr Ph.D. (Age 47)Chief Research & Development Officer Comp: $644.5kMr. Jim Beitel M.B.A.Senior Vice President of Corporate DevelopmentDr. Jerome Bressi Ph.D.Senior Vice President of Regulatory & QualityDr. Barbara HickingbottomSenior VP of Clinical DevelopmentMore ExecutivesKey CompetitorsAdaptimmune TherapeuticsNASDAQ:ADAPCellectisNASDAQ:CLLSbluebird bioNASDAQ:BLUEAtara BiotherapeuticsNASDAQ:ATRACelyad OncologyNASDAQ:CYADView All CompetitorsInsiders & InstitutionsArtal Group S.A.Bought 360,311 shares on 5/17/2024Ownership: 0.317%Jacobs Levy Equity Management Inc.Sold 616,998 shares on 5/16/2024Ownership: 1.757%Caxton Associates LPBought 290,187 shares on 5/16/2024Ownership: 0.255%Bayesian Capital Management LPBought 20,164 shares on 5/16/2024Ownership: 0.035%California State Teachers Retirement SystemSold 5,430 shares on 5/16/2024Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions FATE Stock Analysis - Frequently Asked Questions Should I buy or sell Fate Therapeutics stock right now? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 1 sell rating, 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares. View FATE analyst ratings or view top-rated stocks. What is Fate Therapeutics' stock price target for 2024? 14 Wall Street analysts have issued 12 month price objectives for Fate Therapeutics' stock. Their FATE share price targets range from $5.00 to $10.00. On average, they expect the company's share price to reach $6.75 in the next year. This suggests a possible upside of 89.1% from the stock's current price. View analysts price targets for FATE or view top-rated stocks among Wall Street analysts. How have FATE shares performed in 2024? Fate Therapeutics' stock was trading at $3.74 on January 1st, 2024. Since then, FATE shares have decreased by 4.5% and is now trading at $3.57. View the best growth stocks for 2024 here. Are investors shorting Fate Therapeutics? Fate Therapeutics saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 22,340,000 shares, an increase of 7.4% from the May 15th total of 20,810,000 shares. Based on an average daily trading volume, of 2,530,000 shares, the short-interest ratio is currently 8.8 days. View Fate Therapeutics' Short Interest. When is Fate Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our FATE earnings forecast. How were Fate Therapeutics' earnings last quarter? Fate Therapeutics, Inc. (NASDAQ:FATE) released its earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, meeting the consensus estimate of ($0.47). The biopharmaceutical company had revenue of $1.93 million for the quarter, compared to the consensus estimate of $0.80 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 46.49% and a negative net margin of 2,933.79%. During the same period last year, the firm posted ($0.19) earnings per share. What ETFs hold Fate Therapeutics' stock? ETFs with the largest weight of Fate Therapeutics (NASDAQ:FATE) stock in their portfolio include WisdomTree BioRevolution Fund (WDNA) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH).Tema Oncology ETF (CANC). What is Scott Wolchko's approval rating as Fate Therapeutics' CEO? 2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Fate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD). Who are Fate Therapeutics' major shareholders? Fate Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.71%), Bellevue Group AG (4.25%), Assenagon Asset Management S.A. (2.24%), Jacobs Levy Equity Management Inc. (1.76%), Baker BROS. Advisors LP (1.60%) and Acadian Asset Management LLC (1.51%). Insiders that own company stock include Bahram Valamehr, Brian T Powl, Cindy Tahl, Edward J Dulac III, J Scott Wolchko, John Mendlein, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal, Yuan Xu and Yu-Waye Chu. View institutional ownership trends. How do I buy shares of Fate Therapeutics? Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FATE) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.